Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909584 · ClinicalTrials.gov registry record · Phase 2
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia
A Phase 2 study, sponsored by Telik.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00909584: Clinical Trial Phase 2 study, sponsored by Telik.
NCT00909584 is a Phase 2 study that was terminated before completion, run by Telik. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00909584, a Phase 2 study, was terminated before completion, sponsored by Telik.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a multicenter Phase 2 randomized parallel-group study to determine the effect of Telintra treatment on severe chronic neutropenia. Patients will be randomized to Telintra or enter an observation period with an option to crossover to Telintra treatment in a 1:1 allocation.
Interventions
- DRUG Ezatiostat Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Why NCT00909584 stopped before completion
NCT00909584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Ezatiostat Hydrochloride is the first listed.
NCT00909584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00909584 about?
NCT00909584 is a clinical study titled "Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia". This is a multicenter Phase 2 randomized parallel-group study to determine the effect of Telintra treatment on severe chronic neutropenia. Patients will be randomized to Telintra or enter an observation period with an option to crossover to Telintra treatment in a 1:1 allocation.
What is the current status of trial NCT00909584?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00909584?
The interventions under investigation include: Ezatiostat Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00909584?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00909584's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia